TMSB4Y is a candidate tumor suppressor on the Y chromosome and is deleted in male breast cancer

Oncotarget

Volumn 6, Issue 42, 2015, Pages 44927-44940

  Wong, Hong Yuen ^a   Wang, Grace M ^a   Croessmann, Sarah ^a   Zabransky, Daniel J ^a   Chu, David ^a   Garay, Joseph P ^a   Cidado, Justin ^a,f   Cochran, Rory L ^a   Beaver, Julia A ^a   Aggarwal, Anita ^b,c,d   Liu, Min Ling ^b,d   Argani, Pedram ^a   Meeker, Alan ^a   Hurley, Paula J ^a   Lauring, Josh ^a   Park, Ben Ho ^a,e  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

^d GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^e Johns Hopkins University   (United States)

^f ASTRAZENECA   (United Kingdom)

Author keywords

Cancer genetics; Male breast cancer; TMSB4Y; Tumor suppressor; Y chromosome

Indexed keywords

BETA ACTIN; ACTIN; THYMOSIN; THYMOSIN BETA(4); TUMOR SUPPRESSOR PROTEIN;

ACTIN FILAMENT; ARTICLE; BREAST CARCINOGENESIS; CANCER PATIENT; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CHROMOSOME LOSS; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DEGRADATION; EPITHELIUM CELL; EXON; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE EXPRESSION; GENE INTERACTION; GENE LOCUS; HUMAN; INTRON; MALE BREAST CANCER; METAPHASE; TMSB4Y GENE; TUMOR SUPPRESSOR GENE; X CHROMOSOME; Y CHROMOSOME; BREAST TUMOR; CELL LINE; CELL SHAPE; CELL TRANSFORMATION; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; MALE; MAMMARY GLAND; METABOLISM; PATHOLOGY; PHENOTYPE; POLYMERASE CHAIN REACTION; TIME FACTOR;

ACTINS; BREAST NEOPLASMS, MALE; CELL LINE; CELL PROLIFERATION; CELL SHAPE; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOMES, HUMAN, Y; FEMALE; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MAMMARY GLANDS, HUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; THYMOSIN; TIME FACTORS; TRANSFECTION; TUMOR SUPPRESSOR PROTEINS;

EID: 84953449967     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6743     Document Type: Article

References (41)

1. Ottini L, Palli D, Rizzo S, Federico M, Bazan V and Russo A. Male breast cancer. Crit Rev Oncol Hematol. 2010; 73:141-155.
2. Rizzolo P, Silvestri V, Tommasi S, Pinto R, Danza K, Falchetti M, Gulino M, Frati P and Ottini L. Male breast cancer: genetics, epigenetics, and ethical aspects. Ann Oncol. 2013; 24 Suppl 8:viii75-viii82.
3. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009; 59:225-249.
4. Jemal A, Siegel R, Xu J and Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60:277-300.
5. Ly D, Forman D, Ferlay J, Brinton LA and Cook MB. An international comparison of male and female breast cancer incidence rates. Int J Cancer. 2013; 132:1918-1926.
6. Stang A and Thomssen C. Decline in breast cancer incidence in the United States: what about male breast cancer? Breast Cancer Res Treat. 2008; 112:595-596.
7. Speirs V and Shaaban AM. The rising incidence of male breast cancer. Breast Cancer Res Treat. 2009; 115:429-430.
8. Ruddy KJ and Winer EP. Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorship. Ann Oncol. 2013; 24:1434-1443.
9. Cutuli B. Strategies in treating male breast cancer. Expert Opin Pharmacother. 2007; 8:193-202.
10. Nilsson C, Johansson I, Ahlin C, Thorstenson S, Amini RM, Holmqvist M, Bergkvist L, Hedenfalk I and Fjallskog ML. Molecular subtyping of male breast cancer using alternative definitions and its prognostic impact. Acta Oncol. 2013; 52:102-109.
11. Kornegoor R, Verschuur-Maes AH, Buerger H, Hogenes MC, de Bruin PC, Oudejans JJ, van der Groep P, Hinrichs B and van Diest PJ. Molecular subtyping of male breast cancer by immunohistochemistry. Mod Pathol. 2012; 25:398-404.
12. Ge Y, Sneige N, Eltorky MA, Wang Z, Lin E, Gong Y and Guo M. Immunohistochemical characterization of subtypes of male breast carcinoma. Breast Cancer Res. 2009; 11:R28.
13. Callari M, Cappelletti V, De Cecco L, Musella V, Miodini P, Veneroni S, Gariboldi M, Pierotti MA and Daidone MG. Gene expression analysis reveals a different transcriptomic landscape in female and male breast cancer. Breast Cancer Res Treat. 2011; 127:601-610.
14. Johansson I, Ringner M and Hedenfalk I. The landscape of candidate driver genes differs between male and female breast cancer. PLoS One. 2013; 8:e78299.
15. Noordam MJ and Repping S. The human Y chromosome: a masculine chromosome. Curr Opin Genet Dev. 2006; 16:225-232.
16. Bachtrog D. Y-chromosome evolution: emerging insights into processes of Y-chromosome degeneration. Nat Rev Genet. 2013; 14:113-124.
17. Teixeira MR, Pandis N, Dietrich CU, Reed W, Andersen J, Qvist H and Heim S. Chromosome banding analysis of gynecomastias and breast carcinomas in men. Genes Chromosomes Cancer. 1998; 23:16-20.
18. Balazs M, Mayall BH and Waldman FM. Interphase cytogenetics of a male breast cancer. Cancer Genet Cytogenet. 1991; 55:243-247.
19. Mitchell EL. A cytogenetic study of male breast cancer. Cancer Genet Cytogenet. 1990; 47:107-112.
20. Cochran RL, Cravero K, Chu D, Erlanger B, Toro PV, Beaver JA, Zabransky DJ, Wong HY, Cidado J, Croessmann S, Parsons HA, Kim M, Wheelan SJ, Argani P and Park BH. Analysis of BRCA2 loss of heterozygosity in tumor tissue using droplet digital polymerase chain reaction. Hum Pathol. 2014; 45:1546-1550.
21. Zhu XB, Feng Y, Zhi EL, Fan WM and Zhang AJ. [Y chromosome microdeletions: detection in 1,052 infertile men and analysis of 14 of their families]. Zhonghua Nan Ke Xue. 2014; 20:637-640.
22. Zhang YS, Dai RL, Wang RX, Zhang HG, Chen S and Liu RZ. Analysis of Y chromosome microdeletion in 1738 infertile men from northeastern China. Urology. 2013; 82:584-588.
23. Iijima M, Koh E, Izumi K, Taya M, Maeda Y, Kyono K, Yoshida A and Namiki M. New molecular diagnostic kit to assess Y-chromosome deletions in the Japanese population. Int J Urol. 2014; 21:910-916.
24. Lange J, Skaletsky H, Bell GW and Page DC. MSY Breakpoint Mapper, a database of sequence-tagged sites useful in defining naturally occurring deletions in the human Y chromosome. Nucleic Acids Res. 2008; 36(Database issue):D809-814.
25. Tommasi S, Mangia A, Iannelli G, Chiarappa P, Rossi E, Ottini L, Mottolese M, Zoli W, Zuffardi O and Paradiso A. Gene copy number variation in male breast cancer by aCGH. Cell Oncol (Dordr). 2011; 34:467-473.
26. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C and Schultz N. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013; 6:pl1.
27. Soule HD, Maloney TM, Wolman SR, Peterson WD, Jr., Brenz R, McGrath CM, Russo J, Pauley RJ, Jones RF and Brooks SC. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res. 1990; 50:6075-6086.
28. Yu FX, Lin SC, Morrison-Bogorad M, Atkinson MA and Yin HL. Thymosin beta 10 and thymosin beta 4 are both actin monomer sequestering proteins. J Biol Chem. 1993; 268:502-509.
29. Weber A, Nachmias VT, Pennise CR, Pring M and Safer D. Interaction of thymosin beta 4 with muscle and platelet actin: implications for actin sequestration in resting platelets. Biochemistry. 1992; 31:6179-6185.
30. Pollard TD and Cooper JA. Actin, a central player in cell shape and movement. Science. 2009; 326:1208-1212.
31. Thery M and Bornens M. Cell shape and cell division. Curr Opin Cell Biol. 2006; 18:648-657.
32. Heng YW and Koh CG. Actin cytoskeleton dynamics and the cell division cycle. Int J Biochem Cell Biol. 2010; 42:1622-1633.
33. Fearon ER and Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990; 61:759-767.
34. Forsberg LA, Rasi C, Malmqvist N, Davies H, Pasupulati S, Pakalapati G, Sandgren J, Diaz de Stahl T, Zaghlool A, Giedraitis V, Lannfelt L, Score J, Cross NC, Absher D, Janson ET, Lindgren CM, et al. Mosaic loss of chromosome Y in peripheral blood is associated with shorter survival and higher risk of cancer. Nat Genet. 2014; 46:624-628.
35. Dumanski JP, Rasi C, Lonn M, Davies H, Ingelsson M, Giedraitis V, Lannfelt L, Magnusson PK, Lindgren CM, Morris AP, Cesarini D, Johannesson M, Tiensuu Janson E, Lind L, Pedersen NL, Ingelsson E, et al. Smoking is associated with mosaic loss of chromosome Y. Science. 2015; 347:81-3.
36. Kamper-Jorgensen M. Microchimerism and survival after breast and colon cancer diagnosis. Chimerism. 2012; 3:72-73.
37. Kamper-Jorgensen M, Hjalgrim H, Andersen AM, Gadi VK and Tjonneland A. Male microchimerism and survival among women. Int J Epidemiol. 2014; 43:168-173.
38. Bianchi DW, Zickwolf GK, Weil GJ, Sylvester S and DeMaria MA. Male fetal progenitor cells persist in maternal blood for as long as 27 years postpartum. Proc Natl Acad Sci U S A. 1996; 93:705-708.
39. Vijayakumar S, Garcia D, Hensel CH, Banerjee M, Bracht T, Xiang R, Kagan J and Naylor SL. The human Y chromosome suppresses the tumorigenicity of PC-3, a human prostate cancer cell line, in athymic nude mice. Genes Chromosomes Cancer. 2005; 44:365-372.
40. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC, Asangani IA, Ateeq B, Chun SY, Siddiqui J, Sam L, Anstett M, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature. 2012; 487:239-243.
41. Hindson CM, Chevillet JR, Briggs HA, Gallichotte EN, Ruf IK, Hindson BJ, Vessella RL and Tewari M. Absolute quantification by droplet digital PCR versus analog real-time PCR. Nat Methods. 10:1003-1005.